Literature DB >> 24688108

Understanding the multiple biological aspects leading to myeloma.

Eileen M Boyle1, Faith E Davies, Xavier Leleu, Gareth J Morgan.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24688108      PMCID： PMC3971069          DOI： 10.3324/haematol.2013.097907

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  113 in total

1.  Socioeconomic status and multiple myeloma among US blacks and whites.

Authors:  D Baris; L M Brown; D T Silverman; R Hayes; R N Hoover; G M Swanson; M Dosemeci; A G Schwartz; J M Liff; J B Schoenberg; L M Pottern; J Lubin; R S Greenberg; J F Fraumeni
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

2.  Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis.

Authors:  Sophie Caillard; Lawrence Y Agodoa; Erin M Bohen; Kevin C Abbott
Journal:  Transplantation       Date:  2006-03-27       Impact factor: 4.939

3.  Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.

Authors:  Amel Dib; Bart Barlogie; John D Shaughnessy; Walter Michael Kuehl
Journal:  Blood       Date:  2007-02-01       Impact factor: 22.113

4.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

5.  Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.

Authors:  H J Cohen; J Crawford; M K Rao; C F Pieper; M S Currie
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

6.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Authors:  C Pellat-Deceunynck; S Barillé; G Jego; D Puthier; N Robillard; D Pineau; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

7.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

8.  The resistance mechanisms of proteasome inhibitor bortezomib.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  Biomark Res       Date:  2013-03-01

9.  Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Authors:  Paola E Leone; Brian A Walker; Matthew W Jenner; Laura Chiecchio; Gianpaolo Dagrada; Rebecca K M Protheroe; David C Johnson; Nicholas J Dickens; Jose Luis Brito; Monica Else; David Gonzalez; Fiona M Ross; Selina Chen-Kiang; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.

Authors:  L I Aronson; E L Davenport; F Mirabella; G J Morgan; F E Davies
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528
View more
  8 in total

1.  Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report.

Authors:  Na Zhang; Ting-De Jiang; Shu-Hua Yi
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

Review 2.  Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.

Authors:  Mark E Issa; Farnaz Sedigheh Takhsha; Wim Vanden Berghe; Muriel Cuendet; Chandra Sekhar Chirumamilla; Claudina Perez-Novo
Journal:  Clin Epigenetics       Date:  2017-02-10       Impact factor: 6.551

3.  Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.

Authors:  Maaike V J Braham; Monique C Minnema; Tineke Aarts; Zsolt Sebestyen; Trudy Straetemans; Anna Vyborova; Jurgen Kuball; F Cumhur Öner; Catherine Robin; Jacqueline Alblas
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110

4.  Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.

Authors:  Christian Argueta; Trinayan Kashyap; Boris Klebanov; Thaddeus J Unger; Cathy Guo; Susie Harrington; Erkan Baloglu; Margaret Lee; William Senapedis; Sharon Shacham; Yosef Landesman
Journal:  Oncotarget       Date:  2018-05-22

5.  Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.

Authors:  Adrien Bosseboeuf; Nicolas Mennesson; Sophie Allain-Maillet; Anne Tallet; Eric Piver; Olivier Decaux; Caroline Moreau; Philippe Moreau; Philippe Lehours; Francis Mégraud; Valéry Salle; Edith Bigot-Corbel; Jean Harb; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 6.  Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.

Authors:  Soudeh Ghafouri-Fard; Mahnaz Seifi-Alan; Roshanak Shamsi; Ali Esfandiary
Journal:  Iran J Cancer Prev       Date:  2015-10-27

7.  Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Authors:  L Sanoja-Flores; J Flores-Montero; J J Garcés; B Paiva; N Puig; A García-Mateo; O García-Sánchez; A Corral-Mateos; L Burgos; E Blanco; J Hernández-Martín; R Pontes; M Díez-Campelo; P Millacoy; P Rodríguez-Otero; F Prosper; J Merino; M B Vidriales; R García-Sanz; A Romero; L Palomera; R Ríos-Tamayo; M Pérez-Andrés; J F Blanco; M González; J J M van Dongen; B Durie; M V Mateos; J San-Miguel; A Orfao
Journal:  Blood Cancer J       Date:  2018-11-19       Impact factor: 11.037

8.  Mouse tumor susceptibility genes identify drug combinations for multiple myeloma.

Authors:  Shuling Zhang; Wendy DuBois; Ke Zhang; John K Simmons; V Keith Hughitt; Sayeh Gorjifard; Snehal Gaikwad; Tyler J Peat; Beverly A Mock
Journal:  J Cancer Metastasis Treat       Date:  2020-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.